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Background. Baloxavir marboxil (baloxavir) is expected to reduce influenza transmission by rapid reduction of viral load. The 
incidence of household transmission was compared between index patients (IPs) treated with baloxavir and those treated with neu-
raminidase inhibitors.
Methods. Using a Japanese claims database, the first family members with influenza diagnosis during the 2018–2019 influenza 
season were identified as IPs, and the diagnosis date was designated day 1. According to the anti-influenza drug dispensed to the 
IP, their families were classified into the oral baloxavir group and 3 controls: oral oseltamivir group (a primary control), inhaled 
zanamivir group, and inhaled laninamivir group. A household transmission was defined as influenza diagnosed for any non-IP 
family members during days 3−8. The incidence of household transmission was compared between groups using a logistic regression 
model adjusting backgrounds of IPs.
Results. The proportion of families with household transmission was 17.98% (15 226 of 84 672) in the baloxavir group and 
24.16% (14 983 of 62 004) in the oseltamivir group. The covariate-adjusted odds ratio (oseltamivir/baloxavir) was 1.09 (95% confi-
dence interval [95% CI], 1.05–1.12), which indicated significantly lower incidence in the baloxavir group. The adjusted odds ratios 
(controls/baloxavir) against zanamivir and laninamivir were 0.93 (95% CI, .89–.97) and 0.99 (95% CI, .96–1.02), respectively.
Conclusions. Baloxavir may contribute to reduction in household transmission compared with oseltamivir. In comparison be-
tween baloxavir and inhalants, a similar reduction was not shown and it might be due to unmeasured confounding by administration 
route differences.
Keywords.  influenza virus; baloxavir marboxil; neuraminidase inhibitors; oseltamivir; Japan.
Seasonal influenza is a global health threat, with 1 billion cases, 
3–5 million severe cases, and 290 000–650 000 respiratory 
deaths per year worldwide [1]. In Japan, seasonal influenza be-
gins in November to December and ends in April to May and 
affects more than 10 million people each year [2]. From a public 
health perspective, it is important not only to obtain early alle-
viation of influenza symptoms but also to inhibit transmission 
of influenza virus from infected individuals to surrounding 
people, including family members. Several studies have sug-
gested that treatment of primarily infected patients with an 
anti-influenza drug may reduce household transmission [3–
11]. Baloxavir marboxil (BXM), an anti-influenza drug with a 
novel mechanism of action (cap-dependent endonuclease in-
hibitor), was approved in February 2018 in Japan. In a clinical 
study of patients with uncomplicated influenza, BXM rapidly 
reduced the viral load compared with oseltamivir (OTV), a 
neuraminidase inhibitor (NAI) [12]. BXM is expected to help 
reduce influenza transmission by reducing viral shedding.
Health insurance claims data can be used in extensive re-
search without burdening medical institutions, patients, and pa-
tients’ families. A previous study of household transmission used 
a health insurance claims database to compare the incidence of 
household transmission among users of NAIs [3]. In this study, 
we used the same database to compare the incidence of house-
hold transmission in the 2018–2019 influenza season when 
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METHODS
Database
The data source of this study was the JMDC Claims Database 
(JMDC-DB) provided by JMDC Inc. The JMDC-DB comprises 
Japanese health insurance claims data of insured members and con-
tains medical claims, diagnosis procedure combination claims, and 
dispense claims in a cumulative population of approximately 7.3 
million people from January 2005 through April 2019. Family rela-
tionships among the insured members can be identified by a unique 
family code contained in the JMDC-DB. This study used data from 
October 2018 through April 2019, which includes most patients in 
the 2018–2019 influenza season. All data in the database are an-
onymized in such a manner that no single patient can be identified.
Study Design and Definitions of Exposure and Outcome
This study used a cohort design with active comparators to 
reduce confounding by unmeasured patient characteristics 
[13]. This study was registered at University Hospital Medical 
Information Network Clinical Trials Registry (UMIN-CTR) as 
UMIN000038155 and then conducted.
The first family members with a diagnosis of influenza 
(International Classification of Diseases, Tenth Revision, Clinical 
Modification: J09, J10, and J11) were identified as IPs, and the 
date of diagnosis was designated day 1.
The families were grouped based on the anti-influenza drug 
dispensed to the IP on day 1. The exposed group was the fam-
ilies of IPs dispensed BXM on day 1, and the primary control 
group was the families of IPs dispensed oseltamivir (OTV), an 
oral NAI. Other control groups consisted of zanamivir (ZNV) 
and laninamivir (LNV), which are inhaled NAIs. Peramivir 
(PRV), another NAI that requires intravenous infusion and can 
be administered for consecutive days according to symptoms 
or when patients are not amenable to oral or inhaled treatment, 
was not included in the control group because of presumable 
differences in patient characteristics between PRV and BXM.
Household transmission of influenza virus was defined as in-
fluenza diagnosed for any non-IP family member during days 
3–8.
Definitions of Study Population and Primary Analysis Population
The study population was extracted according to the study in-
clusion criteria (families for which day 1 was from 1 October 
2018 through 23 April 2019; families that included an IP who 
was diagnosed with influenza on day 1 on an outpatient basis; 
and families that included an IP to whom BXM, OTV, ZNV, or 
LNV was dispensed on day 1 and the study exclusion criteria 
(families containing no family member other than an IP as of 
the month of day 1 and families containing ≥2 IPs).
The primary analysis population was the study population 
that met the analysis inclusion criterion (all family members 
as of day 1 had been insured since October 2018) and none of 
the analysis exclusion criteria (families that included an IP who 
was hospitalized on days 1–2 and families that included an IP to 
whom multiple anti-influenza drugs [BXM, OTV, ZNV, LNV, or 
PRV] were dispensed on days 1–2).
Statistical Analyses
The primary end point was the onset of household transmis-
sion. Using a logistic regression model with the presence or ab-
sence of household transmission as the response, the odds ratios 
(ORs; controls/BXM) and its confidence interval (CI) were cal-
culated after adjusting covariates (family size after excluding 
the IP, age category of the IP, sex, family role, scale of medical 
facility, month of onset, type of influenza virus) to compare the 
incidence of household transmission between the BXM group 
and the control group.
Sensitivity analyses were performed by changing the evalua-
tion period for household transmission to days 3–6, days 3–7, 
days 2–6, days 2–7, and days 2–8 by incorporating testing in the 
definition of onset of influenza, by incorporating the prescribed 
anti-influenza drug in the definition of onset of influenza in a 
family member, and by changing the analysis inclusion crite-
rion/analysis exclusion criteria (the analysis inclusion criterion 
was not applied, the exclusion period based on hospitalization 
was not applied/changed to days 1–8, and the exclusion pe-
riod based on treatment with multiple anti-influenza drugs was 
changed to days 1–8 and day 1).
Subgroup analyses by the type of influenza virus, month of 
onset, and age group of the IP were also performed.
SAS 9.4 (SAS Institute, Cary, NC) was used for the statistical 
analyses. Missing data were not imputed. A 2-sided significance 
level of 5% was used, and no adjustment for multiplicity due to 
repeated testing was performed.
RESULTS
Analysis Population
In total, 208 225 families were identified as the primary analysis 
population in the JMDC-DB (Figure 1). In the primary analysis 
population, the BXM group was the largest (84 672 families), 
followed by the OTV group (62 004 families). In IPs, the most 
common age group was 19–64 years (47.5%) in the BXM group 
and ≤6  years (52.1%) in the OTV group (Table  1). Influenza 
type A  was predominant in the IPs with an identified virus 
type. The most common month of onset was January, which 
accounted for 65.8% of all IPs.
Incidence of Household Transmission
The proportion of families with household transmission was 
17.98% (15  226 of 84  672) in the BXM group and 24.16% 
(14 983 of 62 004) in the OTV group, which was the primary 
control group (Figure  2). The covariate-adjusted odds ratio 
(aOR, control/BXM) was calculated using a logistic regres-
sion model. In the comparison between the OTV group and 
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indicates a significantly lower odds of household transmission 
in the BXM group.
The proportion of families with household transmission was 
18.41% (2593 of 14 085) and 17.43% (8272 of 47 464) in the in-
halation ZNV and LNV groups, respectively. The aOR for ZNV 
and LNV groups vs BXM group were 0.93 (95% CI, .89–.97) 
and 0.99 (95% CI, .96–1.02), respectively, which shows that the 
BXM group had a significantly higher odds of household trans-
mission than the ZNV group but odds that were similar to those 
of the LNV group.
The ORs of household transmission for each covariate in-
cluded in the analysis are presented in Table 2. The OR relative 
to the population aged 19–64 years was 3.63 (95% CI, 3.42–3.86)
and 2.53 (95% CI, 2.39–2.68) in the populations aged ≤6 years 
and 7–12 years, respectively, which indicates that the incidence 
of household transmission was especially high when the IP was 
aged ≤12 years.
The sensitivity analyses yielded similar results (data not 
shown).
Subgroup Analysis by Viral Type in the IPs
A subgroup analysis by viral type in the IPs showed that the pro-
portion of families with household transmission tended to be 
lower in type B in all drug groups (Figure 3). The aOR (OTV/
BXM) was 1.11 (95% CI, 1.07–1.15) in influenza type A, which 
was similar to that in the overall analysis, and 1.06 (95% CI, 
.71–1.56) in influenza type B, which represented a wider 95% 
CI but revealed no clear viral type–related difference.
Subgroup Analysis by Month of Onset in the IP
A subgroup analysis by month of onset showed that the pro-
portion of families with household transmission was highest in 
January, during which time more IPs were identified than in the 
other months (Figure 4). The aOR (OTV/BXM) was 1.05 to 1.08 
in December to March, which was similar to that in the overall 
analysis, but was higher in October to November (aOR, 1.42; 95% 
CI, 1.01–2.01) and April (aOR, 1.24; 95% CI, .93–1.65), when 
fewer IPs were identified, than in the overall analysis. The aOR 
(ZNV/BXM) was 0.88 to 0.97 in December to March, which was 
<1.00 as in the overall analysis but >1.00 in October to November 
(aOR, 1.17; 95% CI, .76–1.81) and April (aOR, 1.27; 95% CI, .86–
1.88). The aOR (LNV/BXM) was 0.96 to 1.08, which was almost 
identical to that in the overall analysis in all periods.
Subgroup Analysis by Age Category
A subgroup analysis by age category in the IPs showed that the 
proportion of families with household transmission tended to 
be higher in lower age groups of ≤6 years and 7–12 years in all 
drug groups (Figure 5). The aOR (OTV/BXM) was >1.00 (95% 
CI, 1.01–1.22) in all age groups, although the range was wide.
Figure 1. Flow of identification of families included in the study population and analysis population. *1 October 2018 to 23 April 2019. **BXM, OTV, ZNV, LNV. ***Anti-









niversity Library user on 05 N
ovem
ber 2021
e862 • cid 2021:72 (1 June) • Komeda et al
DISCUSSION
In comparison with the OTV group (predefined as the pri-
mary control group), the aOR (OTV/BXM) was 1.09 (95% CI, 
1.05–1.12), which indicates a significantly lower odds of house-
hold transmission in the BXM group. OTV-resistant strains 
were detected in only 1.0% of all AH1pdm strains isolated in 
Figure 2. Comparison of incidence of household transmission among drug groups. *The odds in the BXM group are in the denominator, and the odds in the control group 
are the numerator. **Covariates for the adjustment: index patient (IP) age (≤6, 7–12, 13–18, 19–64, and ≥65 years), IP sex, family role of IP, scale of medical facility where IP 
was diagnosed, number of family members (continuous variable), month of onset for IP, type of influenza virus. Abbreviations: BXM, baloxavir marboxil; CI, confidence interval; 
LNV, laninamivir octanoate hydrate; OR, odds ratio; OTV, oseltamivir; ZNV, zanamivir hydrate.
Table 1. Background Factors of Index Patients
Background Factors
BXM OTV ZNV LNV Overall
(N = 84 672) n (%) (N = 62 004) n (%) (N = 14 085) n (%) (N = 47 464) n (%) (N = 208 225) n (%)
Age, years
 ≤6 5493 (6.5) 32 278 (52.1) 745 (5.3) 1916 (4.0) 40 432 (19.4)
 7–12 22 293 (26.3) 10 280 (16.6) 7111 (50.5) 14 617 (30.8) 54 301 (26.1)
 13–18 15 280 (18.0) 2674 (4.3) 3575 (25.4) 10 499 (22.1) 32 028 (15.4)
 19–64 40 254 (47.5) 16 082 (25.9) 2590 (18.4) 19 811 (41.7) 78 737 (37.8)
 ≥65 1352 (1.6) 690 (1.1) 64 (0.5) 621 (1.3) 2727 (1.3)
Sex
 Male 48 399 (57.2) 34 202 (55.2) 7476 (53.1) 26 522 (55.9) 116 599 (56.0)
 Female 36 273 (42.8) 27 802 (44.8) 6609 (46.9) 20 942 (44.1) 91 626 (44.0)
Type of influenza virus
 A 61 246 (72.3) 42 883 (69.2) 9188 (65.2) 33 353 (70.3) 146 670 (70.4)
 B 818 (1.0) 570 (0.9) 193 (1.4) 594 (1.3) 2175 (1.0)
 A and B 24 (0.0) 15 (0.0) 3 (0.0) 6 (0.0) 48 (0.0)
 Unknown 22 584 (26.7) 18 536 (29.9) 4701 (33.4) 13 511 (28.5) 59 332 (28.5)
Number of family members excluding the IP
 <3 40 121 (47.4) 32 636 (52.6) 5378 (38.2) 21 967 (46.3) 100 102 (48.1)
 ≥3 44 551 (52.6) 29 368 (47.4) 8707 (61.8) 25 497 (53.7) 108 123 (51.9)
Family role
 Insured person 22 300 (26.3) 9439 (15.2) 1113 (7.9) 10 684 (22.5) 43 536 (20.9)
 Insured person’s spouse 11 497 (13.6) 4705 (7.6) 757 (5.4) 5740 (12.1) 22 699 (10.9)
 Child 46 272 (54.6) 45 015 (72.6) 11 490 (81.6) 28 937 (61.0) 131 714 (63.3)
 Other (including “unknown”) 4603 (5.4) 2845 (4.6) 725 (5.1) 2103 (4.4) 10 276 (4.9)
Month of onset
 October 2018 146 (0.2) 172 (0.3) 59 (0.4) 181 (0.4) 558 (0.3)
 November 2018 613 (0.7) 421 (0.7) 165 (1.2) 467 (1.0) 1666 (0.8)
 December 2018 11 167 (13.2) 6165 (9.9) 1910 (13.6) 5891 (12.4) 25 133 (12.1)
 January 2019 58 548 (69.1) 40 211 (64.9) 8738 (62.0) 29 515 (62.2) 137 012 (65.8)
 February 2019 11 248 (13.3) 12 165 (19.6) 2519 (17.9) 8977 (18.9) 34 909 (16.8)
 March 2019 1952 (2.3) 1889 (3.0) 409 (2.9) 1470 (3.1) 5720 (2.7)
 April 2019 998 (1.2) 981 (1.6) 285 (2.0) 963 (2.0) 3227 (1.5)
Scale of medical facility that the IP visited
 ≥100 beds 4030 (4.8) 6772 (10.9) 569 (4.0) 4993 (10.5) 16 364 (7.9)
 ≤99 beds 80 642 (95.2) 55 201 (89.0) 13 514 (95.9) 42 460 (89.5) 191 817 (92.1)
 Unknown 0 (0.0) 31 (0.0) 2 (0.0) 11 (0.0) 44 (0.0)
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Japan in the 2018–2019 season [2]. Furthermore, a randomized 
clinical trial [4] suggested the efficacy of OTV in preventing 
household transmission. These results support that BXM may 
more strongly contribute to prevention of household trans-
mission than OTV. BXM has shown superior antiviral activity 
against OTV, especially on H3N2 and B [14]. The result of 
Table 2. Odds Ratios of Household Transmission by Covariates Included in Multivariate Logistic Regression Analysis
Covariate Reference Category Test Category Odds Ratio (95% Confidence Interval)
Number of family members excluding the index patient – a – 1.48 (1.46–1.50)
Age, years 19–64 ≤6 3.63 (3.42–3.86)
  7–12 2.53 (2.39–2.68)
  13–18 1.29 (1.21–1.37)
  ≥65 1.21 (1.08–1.36)
Sex Male Female 0.82 (.80–.84)
Type of influenza virus A B 0.62 (.54–.72)
  A and B 0.68 (.29–1.63)
  Unknown 0.92 (.90–.95)
Family role Insured person Insured person’s spouse 1.19 (1.13–1.25)
  Child 0.56 (.52–.59)
  Other (including “unknown”) 0.63 (.59–.68)
Month of onset January 2019 October 2018 0.49 (.38–.63)
  November 2018 0.65 (.56–.74)
  December 2018 0.85 (.82–.88)
  February 2019 0.72 (.69–.74)
  March 2019 0.75 (.70–.81)
  April 2019 0.80 (.72–.89)
Scale of medical facility ≥100 beds ≤99 beds 0.91 (.87–.95)
  Unknown 0.47 (.17–1.33)
aBecause the number of family members is a continuous variable, the odds ratio per increment was calculated.
Figure 3. Subgroup analysis by viral type: (A) type A and (B) type B. *The odds in the BXM group are in the denominator, and the odds in the control group are the numerator. 
**Covariates for the adjustment: index patient (IP) age (≤6, 7–12, 13–18, 19–64, and ≥65 years), IP sex, family role of IP, scale of medical facility where IP was diagnosed, 
number of family members (continuous variable), month of onset for IP. Abbreviations: BXM, baloxavir marboxil; CI, confidence interval; LNV, laninamivir octanoate hydrate; 
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this study may reflect the stronger antiviral activity of BXM 
than OTV.
The results of the subgroup analysis by month of onset in 
the IPs (Figure 4) indicate that the proportion of families with 
household transmission may be affected by the extent of the 
spread of influenza, in addition to the drugs used. Since IPs 
are infected from nonfamily members, the monthly number 
of IPs is generally proportional to the risk of extrafamilial 
transmission in the relevant month. In this study, the aOR 
(OTV/BXM) was higher in October to November (aOR, 1.42; 
95% CI, 1.01–2.01) and April (aOR, 1.24; 95% CI, .93–1.65) 
when a smaller number of IPs was identified (a nonepidemic 
period) than in the overall analysis. These higher ORs during 
the nonepidemic periods may be more reflective of the influ-
ence of each drug on the incidence of household transmission 
due to the low risk of extrafamilial transmission.
The ORs by covariates included in the logistic regression 
analysis (Table 2) and the proportion of families with household 
transmission in the subgroup analysis by age group (Figure 5) 
showed that the incidence of household transmission was 
higher in lower IP age groups of ≤6 years and 7–12 years than 
in the other groups. This higher risk of household transmission 
affecting children is consistent with the results of another study 
[7].
In a clinical study of pediatric patients aged <12  years, 
BXM-insensitive strains were detected in 23.4% (18/77) of 
patients after treatment [15]. In our study, which could not 
determine whether insensitive strains or relevant household 
transmission occurred, the incidence of household transmis-
sion in the age groups of ≤6  years and 7–12  years was sig-
nificantly lower in the BXM group than in the OTV group 
(Figure  5). Moreover, in the population aged ≤12  years, the 
aOR (OTV/BXM) in the nonepidemic period was as high as 
1.67 (95% CI, 1.15–2.41) in October to November and 1.42 
(95% CI, .96–2.10) in April (Supplementary Figure 1), not 
raising concerns that household transmission may increase 
Figure 4. Subgroup analysis by month of onset: (A) BXM vs OTV, (B) BXM vs ZNV, and (C) BXM vs LNV. *The odds in the BXM group are in the denominator, and the odds in 
the control group are the numerator. **Covariates for the adjustment: index patient (IP) age (≤6, 7–12, 13–18, 19–64, and ≥65 years), IP sex, family role of IP, scale of medical 
facility where IP was diagnosed, number of family members (continuous variable), type of influenza virus. Abbreviations: BXM, baloxavir marboxil; CI, confidence interval; 
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because of the development of insensitive strains in patients 
aged ≤12 years.
In addition to OTV, inhaled ZNV and LNV were included 
in the control groups. The aOR (ZNV/BXM) was 0.93 (95% CI, 
.89–.97), indicating a significantly higher odds of household 
transmission in the BXM group. However, by month of onset, 
the odds of household transmission tended to be lower in the 
BXM group, although not consistently, with an OR of 1.17 (95% 
CI, .76–1.81) in October to November and 1.27 (95% CI, .86–
1.88) in April, which suggests the potential superiority of BXM 
over ZNV as well as OTV. The aOR (LNV/BXM) was 0.99 (95% 
CI, .96–1.02) with no significant difference. The incidence of 
household transmission did not differ markedly between BXM 
and inhaled ZNV or LNV. Although the superior antiviral ac-
tivity on H1N1 by LNV compared with OTV was suggested in 
clinical trials [16, 17], there are no clinical trials that can be used 
for comparison with BXM and inhalants (LNV, ZNV). For this 
reason, it is difficult to discuss the comparability of results of 
the antiviral activity in the clinical setting vs the results of this 
study. Additionally, because inhaled medications are used in pa-
tients who can inhale, confounding may have occurred by the 
severity of respiratory symptoms and other factors, which differ 
from those of oral drugs; therefore, there may be limitations in 
comparisons between BXM and these inhaled medications.
Types of influenza in the IPs and the non-IP family mem-
bers were not always clear as it is not required to report the in-
fluenza type for insurance claims purposes in Japan. For this 
reason, we did not define household transmission as being of 
the same influenza type as the IP. However, we confirmed that 
the non-IP family members were predominantly type B when 
IPs had type B (Supplementary Table 1). This data would sup-
port the prediction that the majority of the events were house-
hold transmissions.
In addition to the presence or absence of BXM, there are 
some differences between this study and a study conducted 
by Nakano and Shiosakai [3], who evaluated the incidence 
of household transmission using the JMDC-DB. Nakano and 
Shiosakai [3] defined the onset of influenza based on treat-
ment with an anti-influenza drug, but we defined the onset 
based on the diagnosis of influenza. The diagnostic informa-
tion used in our study allowed for adjustment and subgroup 
analysis by viral type in the IPs. The lower odds of household 
transmission in type B than in type A (Table 2) indicates that 
the viral type should be taken into consideration. Another 
difference lies in the influenza season analyzed. The number 
of influenza cases per fixed point over several years in Japan 
[18] showed that influenza occurred more frequently during 
a shorter period of time in the 2018–2019 season, which we 
analyzed, than in the 2010–2011 season, which Nakano and 
Shiosakai [3] analyzed. In our study, the estimated propor-
tion of families with household transmission was higher and 
varied more markedly according to month of onset than in 
the study by Nakano and Shiosakai [3], which indicates that 
extrafamilial transmission may have been more influential in 
our study because of the more concentrated occurrence of 
influenza.
Figure 5. Subgroup analysis by age group: (A) ≤6 years, (B) 7–12 years, (C) 13–18 years, (D) 19–64 years, and (E) ≥65 years. *Covariates for the adjustment: index patient 
(IP_ sex, family role of IP, scale of medical facility where IP was diagnosed, number of family members (continuous variable), month of onset for IP, type of influenza virus. 
**The odds in the BXM group are in the denominator, and the odds in the control group are the numerator. Abbreviations: BXM, baloxavir marboxil; CI, confidence interval; 
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Our study has several limitations. First, because family mem-
bers covered by the same health insurance were identified as a 
family, the study results may not have reflected the actual family 
composition or shared household living, as exemplified by a lack 
of data for older patients covered by the national health insur-
ance whose claims data JMDC Inc. did not collect. As a result, the 
estimated proportion of families with household transmission 
may differ from that in families living together. Second, although 
active comparators were included to reduce confounding by un-
measured patient characteristics [13] and although ORs were 
adjusted for various background factors of IPs, unadjusted con-
founding or bias may have still affected the study results. In par-
ticular, confounding by the time from onset of influenza to the 
hospital visit, body temperature, and severity of each influenza 
symptom, which are difficult to collect from claims data, cannot 
be ruled out. Third, the possibility exists for the presence of pre-
existing infection in a non-IP family member prior to IP treat-
ment. However, because the importance of early treatment with 
anti-influenza drugs is well known in Japan [19], it is considered 
that most occurrences of influenza have been confirmed in a 
timely manner. Fourth, the prescription of anti-influenza drugs 
recorded in the JMDC-DB may have been generally intended for 
treatment covered by insurance, but records of prescriptions for 
prophylaxis not covered by insurance might have still been in-
cluded. Because OTV, ZNV, and LNV were approved for prophy-
lactic use during the study period, prescription for prophylaxis 
may have resulted in underestimation of the incidence of house-
hold transmission in these drug groups. Finally, the study results 
were based on the data in only 1 season (2018–2019). Given the 
limited number of type B in this study as well as the yearly dif-
ferences in type A subtypes and time course of the number of 
patients, multiseason studies may be required. A phase 3 study 
to assess the efficacy of BXM to reduce onward transmission of 
influenza in households is ongoing (ClinicalTrials.gov identifier 
NCT03969212). The effect of BXM on household transmission 
suggested by this study will be evaluated.
CONCLUSIONS
Treatment of IPs with BXM results in a significantly lower inci-
dence of household transmission compared with those treated 
with OTV. BXM, which has strong antiviral activity, may con-
tribute to reduction in the risk of household transmission 
compared with OTV, the most widely used influenza antiviral 
worldwide. In comparison between BXM and inhaled medica-
tions, a similar reduction in the risk was not shown and it might 
be due to unmeasured confounding by administration route 
differences. Because this study has several limitations, further 
studies may be required.
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